News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boston Scientific Corporation (BSX)'s Anti-Stroke Watchman Heart Implant Lands A Date With The FDA


11/12/2013 8:16:13 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

An FDA advisory panel is slated to meet next month to discuss whether to recommend approval for Boston Scientific's anti-stroke Watchman heart implant. Boston Scientific (NYSE:BSX) won a date with an FDA advisory panel for its Watchman heart implant after the anti-stroke device met 2 of 3 endpoints in a clinical trial. The Watchman implant, already available in 30 countries, is introduced via catheter and threaded into the heart to close off the left atrial appendage and capture any blood clots that may form there.

Help employers find you! Check out all the jobs and post your resume.

Read at MassDevice


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES